Figures
Abstract
Objectives
To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs).
Method
A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis.
Results
Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11–10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56–16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63–14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjögren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis.
Citation: Franco J-S, Molano-González N, Rodríguez-Jiménez M, Acosta-Ampudia Y, Mantilla RD, Amaya-Amaya J, et al. (2014) The Coexistence of Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Colombians. PLoS ONE 9(10): e110242. https://doi.org/10.1371/journal.pone.0110242
Editor: Jose Crispin, Beth Israel Deaconess Medical Center, United States of America
Received: July 22, 2014; Accepted: September 12, 2014; Published: October 24, 2014
Copyright: © 2014 Franco et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by the School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have indicated that they have no conflicts of interest regarding the content of this article.
Introduction
Autoimmune diseases (ADs) are chronic conditions initiated by the loss of immunological tolerance to self-antigens, and they represent a heterogeneous group of disorders that affect specific target organs or multiple systems. Because of the chronic condition of these diseases, they constitute a significant burden on the health care system, with direct and indirect economic costs and quality of life impairment [1]–[4].
The fact that ADs share several subphenotypes, physiopathological mechanisms, environmental factors, and genetic factors has been called the “autoimmune tautology” and indicates that ADs share common physiopathological mechanisms and a common origin [1]–[9].
The clinical evidence of the autoimmune tautology highlights the coexistence of distinct ADs within an individual, which corresponds to polyautoimmunity, defined as the presence of more than one AD in a single patient [1], [10]. When three or more ADs coexist, this condition is called multiple autoimmune syndrome (MAS) [11]. Factors significantly associated with polyautoimmunity include female gender and familial autoimmunity (i.e., the presence of diverse ADs in multiple members of a nuclear family) [10], [12]. Polyautoimmunity represents the effect of a single genotype on diverse phenotypes [1].
Several subphenotypes are shared by ADs, including cutaneous involvement (i.e., photosensibility, alopecia, Raynaud's phenomenon), arthralgia and arthritis, fatigue, and even cardiovascular disease (CVD) [1], [2]. Polyautoimmunity has been reported in most ADs, including systemic lupus erythematosus (SLE) [10], [13], in which one of the most frequent coexistent disease is antiphospholipid syndrome (APS) [13]. Therefore, the purposes of this study were to examine the prevalence and associated factors of the coexistence of SLE and APS in a cohort of Colombian patients with SLE, as well as to discuss on the coexistence of APS with other ADs.
Patients and Methods
Study population
A cross-sectional analytical study was conducted in 376 Colombian patients with SLE. The subjects have been systematically followed at the Center for Autoimmune Diseases Research (CREA) in Bogota, Colombia. All of the subjects fulfilled the 1997 update of the American College of Rheumatology (ACR) classification criteria for SLE [14].
The patient socio-demographic and cumulative clinical and laboratory data, as well as a household description, were obtained by interview, standardized report form, physical examination and chart review as previously reported [15]. The data were collected in an electronic and secure database. The socio-demographic variables included age at SLE onset, disease duration, educational and socioeconomic status, current occupation, smoking habits, coffee consumption, expositional factors and physical activity. The age at onset (AOD) of the disease was defined as the first subjective experience of the symptom(s) and/or sign(s) described in any of the items of the classification criteria [16]. The duration of disease was considered as the difference between the AOD and the date of the first participation in the study. The educational level was recorded as the number of years of education and was divided into two groups (equal to or more than 9 years and less than 9 years of education) based on the “General Law of Education” in Colombia [17], [18]. The socioeconomic status was categorized on the basis of national legislation and was divided into low (1 and 2), intermediate (3) and high (4–6) status [19]. The smoking habits were assessed as never smoking; 1–6, 6–15, and >15 packages/year; or cessation of cigarette consumption. Coffee intake was asked as yes or not and measured in cups per day (i.e., 1–2, 2–4, >4).
Ethics statement
This study was performed in compliance with Act 008430/1993 of the Ministry of Health of the Republic of Colombia, which classified it as minimal-risk research. All of the patients voluntarily accepted to participate in the study by reading and signing the informed consent. The institutional review board of the Universidad del Rosario approved the study design.
Clinical variables
Clinical and laboratory variables were registered as present or absent at any time during the course of the disease as previously reported [15], [20]. In particular, lupus nephritis was defined as active urinary sediment, or proteinuria >500 mg/24 h or positive renal biopsy (ISN/RNP). Pulmonary compromise was considered in the presence of pulmonary hypertension, or pulmonary embolism or diffuse alveolar hemorrhage. Pleuritis was defined as the presence of pleural rub and/or effusion and/or typical pleuritic pain, and confirmed by chest X-ray or computed tomography. Neurologic involvement included the presence of seizures without any other definable cause, or psychosis lacking any other definable cause, or other conditions such as peripheral neuropathy, stroke, transverse myelitis, chorea, or other central nervous system lesions directly attributable to SLE in the absence of other causes. Autoimmune hemolytic anemia (hematocrit <35%, reticulocyte count >4%, and positive Coombs test), leukopenia (white cells <4000/mm3) and thrombocytopenia (platelets <100000/mm3) were also assessed. Other manifestations such as polyautoimmunity [1], [10], MAS [11], familial autoimmunity, and familial autoimmune disease [12] were also included.
CVD represents a broad spectrum of manifestations (i.e., subphenotypes) such as hypertension (HTN), myocardial infarction (MI), peripheral vascular disease (PVD), and cerebrovascular accidents (i.e., stroke). Since atherosclerosis (AT), the usual cause of CVD, starts when the endothelium becomes damaged, and is considered to be an autoimmune-inflammatory disease, CVD was assessed by characterizing the following five subphenotypes: HTN, defined as having blood pressure ≥140/90 mm Hg recorded as an average of two measurements, with at least a 15-minute interval between the measurements or the use of any antihypertensive medication [21]; a history of stroke; a coronary event [i.e., unstable angina, MI]; a thrombotic event (other than MI and carotid involvement, requiring anticoagulant treatment); and carotid disease (by the Doppler criteria or intima-media thickness ≥0.9). The traditional risk factors assessed and included were smoking [22], type 2 diabetes mellitus [23] and dyslipidemia [24].
Concerning pharmacological treatment, the current or past use of steroid therapy (i.e., prednisolone, methylprednisolone, deflazacort), antimalarials (i.e., cloroquine, hydroxychloroquine), immunosupressors (i.e., azathioprine, mycophenolate mofetil and cyclophosphamide) and biological therapy (i.e., rituximab) were also recorded.
APS polyautoimmunity assessment
All of the patients were systematically assessed and classified for the presence of the following: 1) confirmed APS according to the 2006 update of the classification criteria [i.e., a thromboembolic event and positivity for anti-cardiolipin (aCL) IgG/IgM in medium or high titer, anti-beta 2-glycoprotein 1 (B2GPI) IgG/IgM antibodies or lupus anticoagulant (LAC), on two or more occasions] [25]; 2) positivity for antiphospholipid (aPL) antibodies (i.e., aCL IgG/IgM, B2GPI IgG/IgM or LAC) without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies.
Laboratory measurements
The relevant laboratory variables associated with SLE were registered. Patients underwent measurement of the following antibodies by ELISA using commercial kits (QUANTA Lite, INOVA Diagnostics, San Diego, CA, USA): anti-double strand DNA antibodies (anti-dsDNA), precipitating antibodies to extractable nuclear antigens (ENAs: Sm, U1-RNP, Ro/SS-A, La/SS-B), aCL IgG and IgM, B2GPI IgG and IgM antibodies and rheumatoid factor (RF) IgM. The positive cut-off values were >300 UI for anti-dsDNA; >40 UI aCL (IgG and IgM), and B2GPI (IgG and IgM); >20 UI ENAs; and >6 UI for RF. Additionally, the antinuclear antibodies (ANAs) were measured by indirect immunofluorescence on HEp-2 cell (NOVA Lite™ Hep-2 ANA kit, INOVA Diagnostics, San Diego, CA, USA), according to the manufacturer's instructions. Other autoantibodies, including lupus anticoagulant, anti-Scl 70, -centromere, -mitochondrial, and -smooth muscle antibodies, were recorded. White blood cell and platelet count, hemoglobin levels, mean corpuscular volume, complement (i.e., C3 and C4 levels), venereal disease research laboratory results, and creatinine levels were extracted from each patient's clinical record.
Statistical analysis
First, univariate descriptive statistics were performed. The categorical variables were described by the frequencies. The quantitative continuous variables were described as the mean and standard deviation, as well as the median and interquartile range. The comparisons between group 1 (i.e., confirmed APS) and 3 (i.e., SLE patients with neither APS nor positive aPL autoantibodies) in relation to the other categorical variables, were assessed by chi square tests or Fisher's exact tests when facing small sample sizes. The comparisons between the two groups in relation to the continuous variables were performed with the Kruskal-Wallis test. A logistic regression model with APS and SLE polyautoimmunity as the dependent variable was fit (group 1 vs. group 3). As the independent factors, the model included the variables that were statistically significant in the bivariate analyses and those variables that were biologically plausible. The model was adjusted by gender and duration of the disease. The adequacies of the logistic models were assessed using the Hosmer–Lemeshow goodness-of-fit test. The Nagelkerke R2 (i.e., the pseudo-R2) was used to estimate the percentage of variance explained by the models. The adjusted odds ratios (AOR) were calculated with 95% confidence intervals (CI). The Wald statistical test was used to evaluate the significance of the individual logistic regression coefficients for each independent variable. The statistical analyses were performed in R 3.0.2 [26].
Results
Of the 376 patients with SLE, 91.8% were women. Thirty-five patients fulfilled the classification criteria for APS, with a prevalence of 9.3%, representing the second most common polyautoimmunity, preceded by autoimmune thyroid disease, which disclosed a prevalence of 12%. The range of time elapsed from the SLE onset to the diagnosis of APS was 1 to 7 years. All of the patients had SLE prior to the diagnosis of APS. Out of the 35 patients with APS-SLE, 51.4% had a prior thromboembolic event, 40% pregnancy loss and 8.5% had both. Among the non-criteria manifestations, 9 (26%) patients had pulmonary involvement, of whom 6 had pulmonary hypertension and 3 pulmonary embolism, 6 (17%) patients had thrombocytopenia, and 5 (14%) livedo reticularis. Regarding CVD, this was present in 22 (63%) patients, of whom 18 had thrombosis and 10 hypertension (29%). There were 2 additional patients with prior thromboembolic and/or obstetric manifestations and positivity for aPL below medium or high titers that were excluded from further analysis, but in whom a “seronegative” APS could not be rule out. The most frequently found aPL antibody was LAC, with a prevalence rate of 51.5%, followed by aCL IgM with 40% and IgG with 33%. B2GPI IgG and IgM were positive in 11% and 13% of the patients, respectively. Of the SLE patients, 60% had neither APS nor positivity for aPL antibodies. The characteristics of the cohort are illustrated in Table 1. Socioeconomic status, smoking and coffee intake had no significant influence of the coexistence of SLE-APS. Although SLE disease activity index (SLEDAI) was calculated upon study entry, this variable was not included in the analysis.
Factors associated with APS polyautoimmunity
There was no difference in the patient age, AOD or duration of SLE. CVD, Sjögren's syndrome (SS), pulmonary involvement and positivity for RF were risk factors significantly associated with APS. The presence of alopecia was negatively associated with APS (Table 2).
The adjusted effects of the risk factors for APS polyautoimmunity
As expected, CVD was associated with APS-SLE. The main subphenotypes associated with CVD in APS-SLE were thrombosis and hypertension. Additional variables influencing this condition were pulmonary involvement and positivity for RF, regardless of gender and duration of the disease. Alopecia was confirmed to be negatively associated with APS (Table 3). A second logistic regression model was fit to evaluate the effect of aPL alone (i.e., group 2) on the expression of SLE without APS nor positivity for aPL antibodies (i.e., group 3). An association between aPL and RF was observed, but not with clinical features.
Discussion
In our series, the coexistence of APS with SLE was 9.3% and was associated with a distinctive subphenotype characterized by a higher risk of CVD, pulmonary involvement and positivity for RF.
The interplay between SLE and APS has been analyzed over the years, since APS was initially not considered to be a systemic AD and was thought to occur only in patients with SLE [27]–[29]. Furthermore, APS has been found to be associated with systemic manifestations (e.g., non-thrombotic renal disease, migraine, livedo reticularis, pulmonary hypertension, MI) and laboratory features (e.g., positive ANAs, hypocomplementemia) also present in patients with SLE, complicating the clear differentiation between these entities [27]–[29]. However, rather than being the spectrum of the same disease, the coexistence of APS and SLE is a reflection of complex disease traits and highlights the common mechanisms shared by ADs [1], [4].
The association between CVD and SLE mortality was first established by Urowitz et al. [30], with the description of the bimodal pattern of mortality in SLE patients, with an early death due to active disease and infections, and a late death secondary to CVD. Despite a reduction in SLE mortality over the years, CVD remains prevalent among these patients, affecting up to 28% of patients after four decades of disease duration [31], [32]. Traditional risk factors have been described for CVD in SLE (e.g., HTN, dyslipidemia) [33]. However, Esdaile et al. [34] demonstrated that these factors do not fully account for the accelerated AT in these patients, suggesting that there are factors related with the disease involved in the development of CVD. Among the novel risk factors described, polyautoimmunity with APS has been associated with CVD. In fact, APS has been reported as a non-traditional risk factor for CVD in SLE [15]. Other studies have reported similar results, as well as an increased accrual of damage measured by the SLE Damage Index [35]–[38]. Different mechanisms involving the role of aPL in the process of AT have been described, and these include overexpression of tissue factor, annexin I and II, cytokines and other mediators of endothelial dysfunction [39]–[41]; oxidative perturbations and mitochondrial dysfunction [42]; and cross-reactivity with oxidized low-density lipoproteins, accelerating their influx into macrophage and AT development [43]. Recently, Perez-Sanchez et al. [44] found a close relationship between patients with APS and those with polyautoimmunity of SLE and APS in the groups of genes belonging to the cluster of AT, highlighting the role of novel risk factors in the development of CVD among these patients.
The pulmonary involvement described in SLE and APS may be similar, and include pulmonary hypertension, pulmonary embolism and diffuse alveolar hemorrhage [45]–[47]. In our results, the association with pulmonary involvement was driven by the presence of pulmonary hypertension. aPL has been associated with the development of pulmonary hypertension in patients with SLE [48]–[51]. The positivity for RF seem to have a dual role in autoimmunity with a protective effect by interfering with the binding complement system to immune complexes, or a harmful effect by enhancing immune mediated tissue damage [52]. In SLE, positivity for RF has been found to have a protective role in the development of lupus nephritis [53]–[55]. In our results, we found that the positivity for FR IgM was associated with the coexistence of APS and SLE, as well as with the positivity for aPL antibodies. Similarly, Spadaro et al. [52] previously reported the relationship between different isotypes of RF in patients with APS and SLE polyautoimmunity. Positivity for RF IgG was negatively associated with serosal and hematological involvement, and negatively correlated with aCL IgG titer, suggesting that RF IgG is related with the absence of APS; on the other hand, RF IgM was associated with aCL IgM positivity, implying a possible relation with APS [52]. The interplay of RF isotypes in ADs and polyautoimmunity requires further investigation.
As already mentioned, APS was primarily recognized in patients with SLE and was, therefore, considered to be an overlap syndrome (i.e., “secondary” APS). The major difference between polyautoimmunity and overlap syndrome is that the former is the presence of two or more well-defined autoimmune conditions (i.e., overt clinical manifestations mediated by T or B cell responses) fulfilling the validated classification criteria whereas the latter is the partial presence of signs and symptoms of diverse ADs [1]. An overlap syndrome may evolve towards a well-defined phenotype or remain as an undifferentiated AD for years (i.e., the presence of some subphenotypes) [1]. The international consensus statement on an update of the classification criteria for definite APS advised against using the term “secondary” APS because no difference was found in the clinical consequences of aPL antibodies among the patients in this category (Evidence Level I) [25]. The consensus is that, rather than distinguishing patients by “primary” and “secondary” APS, documenting the coexistence of SLE (or other ADs) is more advantageous for classification [25]. In agreement with this argument, we have proposed the term "polyautoimmunity" instead of secondary AD to refer to the coexistence of two or more ADs [10].
Besides SLE, APS has been described in most ADs, including rheumatoid arthritis, SS, autoimmune thyroid diseases, systemic sclerosis (SSc), systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) [35]–[37], [56]–[89]. Moreover, the coexistence of APS with other ADs may be associated with a modified clinical course, especially in SSc (i.e., associated with pulmonary arterial hypertension and MI), PBC (i.e., higher Mayo risk score) and AIH (i.e., associated with cirrhosis and disease activity) (Table 4). Therefore, APS should be addressed in patients with the aforementioned ADs.
Although our study sample size was not negligible, as a cross-sectional study, it would have been more valuable to have had an appropriate follow up to address the association of APS and SLE polyautoimmunity by the inclusion of other measurements such as antibodies isotypes (e.g., B2GPI IgA [90], RF IgG), serologic biomarkers and genetic markers.
Conclusions
APS is considered a systemic AD, and may coexist with other ADs, SLE being the most frequent. The coexistence of APS and SLE is associated with a more severe subphenotype characterized by a higher CVD rate and pulmonary involvement. CVD is a major cause of morbidity and mortality in SLE patients. Novel risk factors related to autoimmunity are recognized because the traditional risk factors do not completely explain the high CVD rates. APS polyautoimmunity should be addressed in every SLE patient to identify the higher risk population and encourage prevention strategies and early therapeutic intervention. APS should be included as a non-traditional risk factor for CVD in SLE and other ADs in further studies.
Acknowledgments
We thank all patients for their participation in the study, and colleagues at the Center for Autoimmune Diseases Research (CREA) for their fruitful discussions and contributions.
Author Contributions
Conceived and designed the experiments: JMA. Performed the experiments: JSF NMG YAA MRJ JMA. Analyzed the data: JSF NMG MRJ JAA JMA. Contributed reagents/materials/analysis tools: JMA JSF NMG YAA MRJ RDM ARV. Wrote the paper: JSF NMG MRJ YAA RDM JAA ARV JMA.
References
- 1. Anaya JM (2014) The diagnosis and clinical significance of polyautoimmunity. Autoimmun Rev 4–5: 4–7.
- 2.
Anaya JM, Rojas-Villarraga A, Shoenfeld Y (2013) From the mosaic of autoimmunity to the autoimmune tautology. In: Anaya JM, Rojas-Villarraga A, Shoenfeld Y, Levy R, Cervera R, editors. Autoimunity From bench to bedside. Bogotá: Editorial Universidad del Rosario. pp. 237–245.
- 3.
Anaya JM, Rojas-Villarraga A, García-Carrasco M (2012) The autoimmune tautology: from polyautoimmunity and familial autoimmunity to the autoimmune genes. Autoimmune Dis 2012.
- 4. Anaya JM (2010) The autoimmune tautology. Arthritis Res Ther 12: 147.
- 5. Shoenfeld Y, Isenberg DA (1989) The mosaic of autoimmunity. Immunol Today 10: 123–6.
- 6. Anaya JM, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y (2007) The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol 3: 623–35.
- 7. Anaya JM (2012) Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 11: 781–4.
- 8. Cifuentes RA, Restrepo-Montoya D, Anaya JM (2012) The autoimmune tautology: an in silico approach. Autoimmune Dis 2012: 792106.
- 9.
Rojas-Villarraga A, Castellanos-delahoz J, Perez-Fernandez O, Amaya-Amaya J, Franco JS, et al. (2013) The autoimmune ecology. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, Levy R, Cervera R, editors. Autoimunity From bench to bedside. Bogotá: Editorial Universidad del Rosario. pp. 322–41.
- 10. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya J-M (2012) Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis 2012: 254319.
- 11. Anaya J-M, Castiblanco J, Rojas-Villarraga A, Pineda-Tamayo R, Levy RA, et al. (2012) The multiple autoimmune syndromes. A clue for the autoimmune tautology. Clin Rev Allergy Immunol 43: 256–64.
- 12. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM (2013) How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med 11: 73.
- 13. Rojas-Villarraga A, Toro C-E, Espinosa G, Rodríguez-Velosa Y, Duarte-Rey C, et al. (2010) Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev 9: 229–32.
- 14. Klippel J, Lahita R, Esdaile JM, Hahn BH, Urowitz MB, et al. (1999) Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 42: 1785–96.
- 15. Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, Molano-González N, Mantilla RD, et al. (2013) Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis 2013: 794383.
- 16. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
- 17.
Ministry of Education (1992) Law of Higher Education – Law 30 of 1992. Government of Colombia. Available: http://www.mineducacion.gov.co/1621/articles-86437_Archivo_pdf.pdf. Accessed 2014 Jul 10.
- 18.
Ministry of Education (1994) Law 115 of 1994. Government of Colombia. Available: http://www.mineducacion.gov.co/1621/articles-85906_archivo_pdf.pdf. Accessed 2014 Jul 10.
- 19. Calixto OJ, Anaya JM (2014) Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev 13: 641–54.
- 20. Anaya JM, Cañas C, Mantilla RD, Pineda-Tamayo R, Tobón GJ, et al. (2011) Lupus nephritis in Colombians: contrasts and comparisons with other populations. Clin Rev Allergy Immunol 40: 199–207.
- 21. Jones DW, Hall JE (2004) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 43: 1–3.
- 22. Toloza SMA, Uribe AG, McGwin G, Alarcón GS, Fessler BJ, et al. (2004) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 50: 3947–57.
- 23. American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37 (Suppl 1)S81–90.
- 24. Stone NJ, Bilek S, Rosenbaum S (2005) Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 96: 53E–59E.
- 25. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295–306.
- 26.
Team RC (2013) R: A language and environment for statistical computing.
- 27. Agmon-Levin N, Shoenfeld Y (2014) The spectrum between antiphospholipid syndrome and systemic lupus erythematosus. Clin Rheumatol 33: 293–5.
- 28. Taraborelli M, Andreoli L, Tincani A (2012) Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a “systemic disease”. Best Pract Res Clin Rheumatol 26: 79–90.
- 29. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11: 593–5.
- 30. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, et al. (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221–5.
- 31. Nikpour M, Gladman DD, Urowitz MB (2013) Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? Lupus 22: 1243–50.
- 32. Urowitz MB, Gladman DD, Tom BDM, Ibañez D, Farewell VT (2008) Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus. J Rheumatol 35: 2152.
- 33. Nikpour M, Urowitz MB, Gladman DD (2009) Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep 11: 248–54.
- 34. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331–7.
- 35. Mok CC, Chan PT, Ho LY, Yu KL, To CH (2013) Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study. Medicine (Baltimore) 92: 217–22.
- 36.
Signorelli FV, Salles GF, Papi JA (2011) Antiphospholipid syndrome as predictor of mortality in Brazilian patients with systemic lupus erythematosus. Lupus 20: article 419.
- 37. Ruiz-Irastorza G, Egurbide M-V, Ugalde J, Aguirre C (2004) High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 164: 77–82.
- 38. Soares M, Reis L, Papi JAS, Cardoso CRL (2003) Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients. Lupus 12: 788–94.
- 39. Cuadrado MJ, López-Pedrera C, Khamashta MA, Camps MT, Tinahones F, et al. (1997) Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 40: 834–41.
- 40. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, et al. (2010) Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34: 105–10.
- 41. López-Pedrera C, Cuadrado MJ, Herández V, Buendia P, Aguirre MA, et al. (2008) Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 58: 2835–44.
- 42. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, et al. (2012) Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 119: 5859–70.
- 43. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, et al. (1997) Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107: 569–73.
- 44.
Perez-Sanchez C, Barbarroja N, Messineo S, Ruiz-Limon P, Rodriguez-Ariza A, et al. (2014) Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis DOI:10.1136/annrheumdis-2013-204600.
- 45. Paran D, Fireman E, Elkayam O (2004) Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. Autoimmun Rev 3: 70–5.
- 46. Pego-Reigosa JM, Medeiros DA, Isenberg DA (2009) Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 23: 469–80.
- 47. Stojanovich L (2006) Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 5: 344–8.
- 48. Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, et al. (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31: 183–9.
- 49. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17: 1292–8.
- 50. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J (1992) Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 21: 275–86.
- 51. Alarcón-Segovia D, Delezé M, Oria CV, Sánchez-Guerrero J, Gómez-Pacheco L, et al. (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68: 353–65.
- 52. Spadaro A, Riccieri V, Terracina S, Rinaldi T, Taccari E, et al. (2000) Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus 9: 56–60.
- 53. Skare TL, Silva MBG, Holler AP, Chavez PA (2009) Protective role of rheumatoid factor in lupus nephritis. Clin Exp Rheumatol 27: 895.
- 54. Feldman D, Ginzler E, Kaplan D (1989) Rheumatoid factor in patients with systemic lupus erythematosus. J Rheumatol 16: 618–22.
- 55. Hill GS, Hinglais N, Tron F, Bach JF (1978) Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am J Med 64: 61–79.
- 56. Gao N, Wang ZL, Li MT, Han SM, Dang YQ, et al. (2013) Clinical characteristics and risk factors of intracranial hemorrhage in systemic lupus erythematosus. Lupus 22: 453–60.
- 57. Gould T, Tikly M, Asherson R, Loizou S, Singh S (2006) Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 35: 29–34.
- 58. Vianna JL, Haga HJ, Tripathi P, Cervera R, Khamashta MA, et al. (1992) Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis 51: 160–1.
- 59. Aguirre V, Cuchacovich R, Barria L, Aris H, Trejo C, et al. (2001) Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE). Lupus 10: 75–80.
- 60. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, et al. (2004) The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 50: 1226–32.
- 61. Clowse ME, Magder LS, Witter F, Petri M (2006) Early risk factors for pregnancy loss in lupus. Obstet Gynecol 107: 293–9.
- 62. Palomo I, Pinochet C, Alarcón M, Sandoval R, Gonzalez J, et al. (2006) Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis. J Clin Lab Anal 20: 190–4.
- 63. Jeleniewicz R, Majdan M, Targońska-Stępniak B, Dryglewska M (2012) Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity. Pol Arch Med Wewn 122: 480–6.
- 64. Wolf P, Gretler J, Aglas F, Auer-Grumbach P, Rainer F (1994) Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol 131: 48–51.
- 65. Seriolo B, Fasciolo D, Sulli A, Cutolo M (2001) Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol 19: 561–4.
- 66. Vittecoq O, Jouen-Beades F, Krzanowska K, Bichon-Tauvel I, Menard JF, et al. (2000) Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology (Oxford) 39: 481–9.
- 67. Seriolo B, Accardo S, Garnero A, Fasciolo D, Cutolo M (1999) Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology (Oxford) 38: 675–8.
- 68. Fauchais A, Lambert M, Launay D, Queyrel V, Nguyen N, et al. (2004) Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients. Lupus 13: 245–8.
- 69. Pasoto SG, Chakkour HP, Natalino RR, Viana VST, Bueno C, et al. (2012) Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Clin Rheumatol 31: 1331–8.
- 70. Cervera R, García-Carrasco M, Font J, Ramos M, Reverter JC, et al. (1997) Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 15: 361–5.
- 71. Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, et al. (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35: 312–21.
- 72. Jedryka-Goral A, Jagiello P, D'Cruz DP, Maldykowa H, Khamashta MA, et al. (1992) Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome. Ann Rheum Dis 51: 889–91.
- 73. Paggi A, Caccavo D, Ferri GM, Di Prima MA, Amoroso A, et al. (1994) Anti-cardiolipin antibodies in autoimmune thyroid diseases. Clin Endocrinol (Oxf) 40: 329–33.
- 74. Nabriski D, Ellis M, Ness-Abramof R, Shapiro M, Shenkman L (2000) Autoimmune thyroid disease and antiphospholipid antibodies. Am J Hematol 64: 73–5.
- 75. Díez JJ, Doforno RA, Iglesias P, Sastre J, Gómez-Pan A, et al. (1993) Anticardiolipin antibodies in autoimmune thyroid disease. J Clin Lab Immunol 40: 125–34.
- 76. Osundeko O, Hasinski S, Rose LI (2001) Anticardiolipin antibodies in Hashimoto's disease. Endocr Pract 7: 181–3.
- 77. Assous N, Allanore Y, Batteux F, Meune C, Toulon P, et al. (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23: 199–204.
- 78. Herrick AL, Heaney M, Hollis S, Jayson MI (1994) Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis 53: 540–2.
- 79. Enzenauer RJ, Collier DH, Lopez LR (2006) Anticardiolipin antibodies in scleroderma. J Clin Rheumatol 12: 324–6.
- 80. Sato S, Fujimoto M, Hasegawa M, Takehara K (2003) Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis 62: 771–4.
- 81. Touré AO, Ly F, Sall A, Diatta A, Gadji M, et al. (2013) Antiphospholipid antibodies and systemic scleroderma. Turkish J Haematol 30: 32–6.
- 82. Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G (1997) Clinical setting of patients with systemic sclerosis by serum autoantibodies. Clin Rheumatol 16: 378–83.
- 83. Gupta R, Thabah MM, Gupta S, Shankar S, Kumar A (2009) Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int 30: 277–9.
- 84. Rees JD, Lança S, Marques PV, Gómez-Puerta JA, Moco R, et al. (2006) Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis 65: 109–11.
- 85. Sherer Y, Livneh A, Levy Y, Shoenfeld Y, Langevitz P (2000) Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel overlap syndrome. Lupus 9: 42–6.
- 86. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, et al. (1996) The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101: 576–83.
- 87. Efe C, Wahlin S, Ozaslan E, Berlot AH, Purnak T, et al. (2012) Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol 24: 531–4.
- 88. Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, et al. (2006) Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol 119: 203–12.
- 89. Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, Gatselis N, et al. (2005) Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 24: 251–60.
- 90. Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limón P, Martínez-Martínez LA, et al. (2013) Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65: 3186–93.